Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

EXPert opinions

Commentaries on select publications


recent publications on COVID-19 & PSORIASIS

Severe COVID-19 outcomes in patients with psoriasis.

J Eur Acad Dermatol Venereol. 2020 Aug 11;:

Authors: Lima XT, Cueva MA, Lopes EM, Alora MB

Psoriasis is a chronic inflammatory disease associated with comorbidities known to increase risk of severe COVID-19, such as hypertension, cardiovascular disease, diabetes and obesity.1,2 Use of systemic therapies may increase a patient's risk of infections.3 Our study aims to evaluate the association of psoriasis systemic therapy and COVID outcomes.

PMID: 32780905 [PubMed - as supplied by publisher]

Related Articles

Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey.

J Eur Acad Dermatol Venereol. 2020 Aug 11;:

Authors: Dyrberg Loft N, Halling AS, Iversen L, Vestergaard C, Deleuran M, Rasmussen MK, Zachariae C, Thyssen JP, Skov L

Patients with moderate-to-severe atopic dermatitis (AD) or psoriasis often require systemic immunomodulatory therapy. The uncertainty of the potential of these therapies to increase the risk of more serious illness due to Coronavirus disease 2019 (COVID-19) may have caused anxiety and led to treatment discontinuation. Therefore, we conducted an anonymous questionnaire on concerns of COVID-19 in patients with AD or psoriasis treated with systemic immunomodulatory therapy.

PMID: 32780487 [PubMed - as supplied by publisher]


View all publications from PubMed 


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.